Stockscreener 앱 받기
12.37
0.64%
-0.08
시간 외 거래:
12.37
전일 마감가:
$12.45
열려 있는:
$12.49
하루 거래량:
1.24M
Relative Volume:
0.47
시가총액:
$1.41B
수익:
-
순이익/손실:
$-242.30M
주가수익비율:
-4.9879
EPS:
-2.48
순현금흐름:
$-192.10M
1주 성능:
+4.30%
1개월 성능:
+70.39%
6개월 성능:
+39.15%
1년 성능:
+35.78%
1일 변동 폭
$12.35
$12.61
1주일 범위
$11.79
$12.97
52주 변동 폭
$3.72
$12.97
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
COGT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
12.37 | 1.74B | 0 | -242.30M | -192.10M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
What drives Cogent Biosciences Inc. stock priceExceptional trading performance - Autocar Professional
What analysts say about Cogent Biosciences Inc. stockFree Wealth Planning Blueprint - Autocar Professional
Is Cogent Biosciences Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
Cogent Biosciences Inc. Stock Analysis and ForecastGame-changing returns - jammulinksnews.com
Cogent Biosciences (NASDAQ:COGT) Given New $22.00 Price Target at Citigroup - MarketBeat
3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags - Benzinga
When (COGT) Moves Investors should Listen - news.stocktradersdaily.com
Cogent Biosciences (COGT) Target Price Raised by Citigroup | COG - GuruFocus
Cogent Biosciences stock hits 52-week high at 12.66 USD By Investing.com - Investing.com South Africa
Cogent Biosciences stock hits 52-week high at 12.66 USD - Investing.com
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogent Biosciences | BPMC Stock News - GuruFocus
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogen - GuruFocus
Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating - MSN
Cogent Biosciences: Analyst Maintains Buy Rating Amid Promising Trials and Strategic Advantages - AInvest
Day 11 of Gains Streak for Cogent Biosciences Stock with 67% Return (vs. 52% YTD) [7/16/2025] - Trefis
10 Best Small-Cap Stocks to Buy According to Billionaires - Insider Monkey
COGT Stock Up 62% after 10-Day Win Streak - Trefis
Mintz Advises on Cogent Biosciences’ $230 Million Public Offering - Mintz
Press Release: Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - 富途牛牛
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - MSN
Cogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Guggenheim Reiterates "Buy" Rating for Cogent Biosciences with $17 Price Target - AInvest
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $22.00 at HC Wainwright - MarketBeat
Cogent Biosciences Closes $230 Million Upsized Stock Offering - MarketScreener
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Cogent Biosciences Announces Closing of Upsized Public - GlobeNewswire
Cogent Biosciences Secures Massive $230M Funding for Bezuclastinib Drug Development - Stock Titan
Cogent Biosciences’ Mysterious 5.6% Surge: What’s Behind the Move? - AInvest
Cogent Biosciences' 8% Surge: Unraveling the Mystery Behind the Spike - AInvest
Cogent Biosciences(COGT) Soars 6.34% on Phase III Success - AInvest
Form 424B5 Cogent Biosciences, Inc. - StreetInsider
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results (COGT) - Seeking Alpha
Cogent Biosciences: Drug Trial Triumph Sparks Stock Surge - StocksToTrade
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $17 to $25 - 富途牛牛
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences Prices $200 Million Stock Offering - MarketScreener
Cogent Biosciences (COGT) Prices $200M Public Offering at $9 Per Share - GuruFocus
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges - NewsBreak: Local News & Alerts
Cogent Biosciences Secures Massive $200M Funding to Accelerate Bezuclastinib Development - Stock Titan
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock - The Manila Times
Cogent Biosciences announces pricing of upsized public offering of shares of common stock - MarketScreener
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock | COGT Stock News - GuruFocus
Cogent Biosciences stock falls on $150 million share offering By Investing.com - Investing.com India
After-hours movers: Mobileye, RxSight, Cogent Biosciences By Investing.com - Investing.com Canada
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.91%
0.25%
자본화:
|
볼륨(24시간):